Endocyte, Inc. (ECYT) belonging to the Healthcare sector has surged 22.54% and closed its last trading session at $10.82.
The company reported its EPS on 12/30/2017. Currently, the stock has a 1 Year Price Target of $13.5.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Endocyte, Inc. on 12/30/2017 reported its EPS as $-0.27 with the analysts projecting the EPS of the stock as $-0.32. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 0.156%.
Many analysts have provided their estimated foresights on Endocyte, Inc. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.18.
Whereas they predicted High and Low Earnings Estimate as $-0.16 and $-0.2 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.27.
Analysts are also projecting an Average Revenue Estimate for Endocyte, Inc. as $10000 in the Current Quarter. This estimate is provided by 3 analysts.
Endocyte, Inc. (ECYT) has the market capitalization of $702.54 Million. The company rocked its 52-Week High of $11.54 and touched its 52-Week Low of $1.17.
The stock has Return on Assets (ROA) of -47.7 percent. Return on Equity (ROE) stands at -50.1% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 152.8 Percent. The company has Beta Value of 0.91 and ATR value of 0.89. The Weekly and Monthly Volatility stands at 22.20% and 13.78%.